- Home
- ACOG vs POAS Comparison
ACOG vs POAS Comparison
Compare ACOG & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACOG | POAS |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.5M | 114.0M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ACOG | POAS |
|---|---|---|
| Price | $5.08 | $3.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 84.0K | ★ 505.8K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,427,199.00 | $128,328.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $143.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.75 | $2.98 |
| 52 Week High | $11.54 | $4.30 |
Technical Indicators
Market Signals| Indicator | ACOG | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | N/A |
| Support Level | $5.66 | N/A |
| Resistance Level | $6.74 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout ACOG Alpha Cognition Inc.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.